HCA Healthcare Names John W. Chidsey III as Independent Director to Boost Governance and Strategy.

HCA Healthcare has appointed John W. Chidsey III as an independent director, effective July 15, 2025, increasing the board from nine to ten members. Chidsey, with a background in executive leadership, will serve on key committees, including audit and compliance, compensation, and patient safety and quality of care. This move is seen as a positive development for the company, potentially leading to improved shareholder value.

HCA Healthcare, Inc. (NYSE: HCA), one of the nation's leading healthcare providers, has appointed John W. Chidsey III as an independent director, effective July 15, 2025. This appointment expands the board from nine to ten members, signaling a strategic move to enhance corporate governance and decision-making. Chidsey, who most recently served as the global chief executive officer of Subway, brings extensive experience in leading corporate strategy at large, complex public and private companies.

Chidsey will serve on several key committees, including the audit and compliance committee, compensation committee, and patient safety and quality of care committee. His appointment aligns with the company's Amended and Restated Certificate of Incorporation [1]. This move is expected to bolster HCA Healthcare's commitment to improving healthcare delivery and patient outcomes.

Prior to his role at Subway, Chidsey held senior leadership positions at Burger King Holdings, Inc., Cendant Corporation, and PepsiCo. He currently serves on the board of Norwegian Cruise Line Holdings Ltd. and previously held board positions at Encompass Health Corporation, Burger King Holdings, Inc. (as chairman), and Brinker International, Inc. [2, 3].

HCA Healthcare operates 192 hospitals and approximately 2,500 ambulatory sites of care across 20 states and the United Kingdom. The company has demonstrated strong financial performance with annual revenue of $71.6 billion and EBITDA of $14.2 billion. Analysts have maintained an Overweight rating for HCA Healthcare stock, with price targets ranging from $404 to $444 [2, 3].

References:
[1] https://www.morningstar.com/news/business-wire/20250711903741/hca-healthcare-appoints-john-w-chidsey-iii-as-new-independent-director
[2] https://www.investing.com/news/company-news/hca-healthcare-appoints-former-subway-ceo-john-chidsey-to-board-93CH-4132004
[3] https://www.ainvest.com/news/hca-healthcare-appoints-john-chidsey-board-directors-2507/